SG11202003912RA - Single Domain Antibodies that Bind to CD137 - Google Patents
Single Domain Antibodies that Bind to CD137Info
- Publication number
- SG11202003912RA SG11202003912RA SG11202003912RA SG11202003912RA SG11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA SG 11202003912R A SG11202003912R A SG 11202003912RA
- Authority
- SG
- Singapore
- Prior art keywords
- bind
- single domain
- domain antibodies
- antibodies
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1718735.2A GB201718735D0 (en) | 2017-11-13 | 2017-11-13 | Bispecific molecules that bind to CD137 and PSMA |
GBGB1718734.5A GB201718734D0 (en) | 2017-11-13 | 2017-11-13 | Single domain antibodies that bind to CD137 |
GBGB1808589.4A GB201808589D0 (en) | 2018-05-24 | 2018-05-24 | Single domain antibodies that bind CD137 |
PCT/GB2018/053279 WO2019092451A1 (en) | 2017-11-13 | 2018-11-13 | Single Domain Antibodies that Bind to CD137 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003912RA true SG11202003912RA (en) | 2020-05-28 |
Family
ID=64457031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003912RA SG11202003912RA (en) | 2017-11-13 | 2018-11-13 | Single Domain Antibodies that Bind to CD137 |
SG11202003978UA SG11202003978UA (en) | 2017-11-13 | 2018-11-13 | Molecules that bind to cd137 and psma |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003978UA SG11202003978UA (en) | 2017-11-13 | 2018-11-13 | Molecules that bind to cd137 and psma |
Country Status (10)
Country | Link |
---|---|
US (2) | US20200362051A1 (ru) |
EP (2) | EP3710478A1 (ru) |
JP (3) | JP2021502810A (ru) |
KR (2) | KR20200083574A (ru) |
CN (1) | CN111699197A (ru) |
AU (2) | AU2018363292A1 (ru) |
CA (2) | CA3082321A1 (ru) |
IL (2) | IL274370A (ru) |
SG (2) | SG11202003912RA (ru) |
WO (2) | WO2019092452A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
US11591398B2 (en) | 2017-01-06 | 2023-02-28 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death protein 1 (PD-1) |
GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
KR20200083574A (ko) * | 2017-11-13 | 2020-07-08 | 크레센도 바이오로직스 리미티드 | Cd137 및 psma에 결합하는 분자 |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP2020132572A (ja) * | 2019-02-20 | 2020-08-31 | 旭化成株式会社 | シラノール組成物、硬化物及び製造方法 |
WO2020229842A1 (en) * | 2019-05-15 | 2020-11-19 | Crescendo Biologics Limited | Binding molecules |
CN113166265B (zh) * | 2019-08-12 | 2024-06-04 | 天境生物科技(上海)有限公司 | 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途 |
WO2021093753A1 (zh) * | 2019-11-13 | 2021-05-20 | 合肥瀚科迈博生物技术有限公司 | 一种能够与人4-1bb结合的分子及其应用 |
CR20220221A (es) * | 2019-11-18 | 2022-07-11 | Janssen Biotech Inc | Receptores del antígeno quimérico anti-cd79, células car-t, y uoso de estos |
US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 |
JP2024521701A (ja) * | 2021-05-21 | 2024-06-04 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗cd137抗体及びその使用方法 |
JP2024522078A (ja) * | 2021-05-21 | 2024-06-11 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗gpc3及び抗cd137多重特異性抗体ならびにそれらの使用方法 |
CN113621065B (zh) * | 2021-08-30 | 2023-08-01 | 武汉海沙百得生物技术有限公司 | 靶向4-1bb的全人源抗体及其制备方法和应用 |
KR20240049829A (ko) * | 2021-08-31 | 2024-04-17 | 라노바 메디신즈 리미티드 컴파니 | 항-4-1bb 나노바디 |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
AU2005250499B2 (en) * | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
WO2014141192A1 (en) * | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
IL247715B (en) * | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
IL251010B2 (en) | 2014-10-22 | 2024-01-01 | Crescendo Biologics Ltd | transgenic mice |
AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
MX2017014716A (es) * | 2015-05-18 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Polipeptido de fusion anti-cancer. |
JP7074665B2 (ja) * | 2015-10-07 | 2022-05-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激tnf受容体に対する四価の二重特異性抗体発明の分野 |
JP7022993B2 (ja) * | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の41bb結合融合タンパク質 |
US11236174B2 (en) * | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
CN109195994A (zh) * | 2016-04-22 | 2019-01-11 | 鳄鱼生物科学公司 | 针对cd137的新型双特异性多肽 |
JP2019519223A (ja) * | 2016-05-27 | 2019-07-11 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質 |
MA50352A (fr) * | 2017-10-10 | 2020-08-19 | Numab Therapeutics AG | Anticorps multispécifiques |
KR20200083574A (ko) * | 2017-11-13 | 2020-07-08 | 크레센도 바이오로직스 리미티드 | Cd137 및 psma에 결합하는 분자 |
-
2018
- 2018-11-13 KR KR1020207016092A patent/KR20200083574A/ko not_active Application Discontinuation
- 2018-11-13 US US16/763,063 patent/US20200362051A1/en active Pending
- 2018-11-13 US US16/763,059 patent/US20200362047A1/en active Pending
- 2018-11-13 CA CA3082321A patent/CA3082321A1/en active Pending
- 2018-11-13 CN CN201880085847.0A patent/CN111699197A/zh active Pending
- 2018-11-13 EP EP18808058.4A patent/EP3710478A1/en active Pending
- 2018-11-13 SG SG11202003912RA patent/SG11202003912RA/en unknown
- 2018-11-13 AU AU2018363292A patent/AU2018363292A1/en active Pending
- 2018-11-13 EP EP18808057.6A patent/EP3710477A1/en active Pending
- 2018-11-13 CA CA3082297A patent/CA3082297A1/en active Pending
- 2018-11-13 KR KR1020207016093A patent/KR20200080304A/ko not_active Application Discontinuation
- 2018-11-13 AU AU2018363291A patent/AU2018363291A1/en active Pending
- 2018-11-13 WO PCT/GB2018/053280 patent/WO2019092452A1/en active Application Filing
- 2018-11-13 JP JP2020526245A patent/JP2021502810A/ja active Pending
- 2018-11-13 SG SG11202003978UA patent/SG11202003978UA/en unknown
- 2018-11-13 JP JP2020526175A patent/JP7312168B2/ja active Active
- 2018-11-13 WO PCT/GB2018/053279 patent/WO2019092451A1/en active Application Filing
-
2020
- 2020-04-30 IL IL274370A patent/IL274370A/en unknown
- 2020-04-30 IL IL274371A patent/IL274371A/en unknown
-
2023
- 2023-07-06 JP JP2023111710A patent/JP2023126951A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7312168B2 (ja) | 2023-07-20 |
KR20200083574A (ko) | 2020-07-08 |
JP2021502810A (ja) | 2021-02-04 |
CN111699197A (zh) | 2020-09-22 |
EP3710477A1 (en) | 2020-09-23 |
IL274370A (en) | 2020-06-30 |
WO2019092452A1 (en) | 2019-05-16 |
EP3710478A1 (en) | 2020-09-23 |
CA3082297A1 (en) | 2019-05-16 |
WO2019092451A1 (en) | 2019-05-16 |
AU2018363291A1 (en) | 2020-05-21 |
SG11202003978UA (en) | 2020-05-28 |
US20200362047A1 (en) | 2020-11-19 |
CN111683968A (zh) | 2020-09-18 |
IL274371A (en) | 2020-06-30 |
JP2023126951A (ja) | 2023-09-12 |
US20200362051A1 (en) | 2020-11-19 |
AU2018363292A1 (en) | 2020-05-21 |
CA3082321A1 (en) | 2019-05-16 |
JP2021502104A (ja) | 2021-01-28 |
KR20200080304A (ko) | 2020-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274370A (en) | Single-region antibodies that bind CD137 | |
IL284336B (en) | Treatment using antibodies that bind to ctla4 | |
IL276537A (en) | Antibodies bind to GPRC5D | |
IL254088A0 (en) | Cure using cd137 binding antibody | |
IL261188A (en) | Antibodies against tigit | |
HK1252863A1 (zh) | 結合cd22的抗體分子 | |
HK1252862A1 (zh) | 結合cd45的抗體分子 | |
IL254260A0 (en) | A healing antibody that binds tim3 | |
IL275268A (en) | Antibodies against LILRB2 | |
EP3325009A4 (en) | Antibody therapeutics that bind lag3 | |
HK1256300A1 (zh) | 特異性地結合至tl1a的抗體 | |
EP3247407A4 (en) | Non-immunogenic single domain antibodies | |
ZA201907065B (en) | Monoclonal antibody to pd-l1 | |
EP3297662A4 (en) | ANTIBODY BINDING TO AXL PROTEINS | |
IL269394A (en) | Antibodies bind to STEAP-1 | |
EP3131580A4 (en) | Antibody therapeutics that bind cd147 | |
IL273235A (en) | Heavy chain antibodies that bind to ectoenzymes | |
GB201609742D0 (en) | Improvements relating to antibodies | |
EP3297663A4 (en) | Antibodies that bind to axl proteins | |
ZA202002044B (en) | Monoclonal antibody to il-5rα | |
IL272015A (en) | Antibodies to MADCAM | |
SG10202010600SA (en) | T cell receptor like antibodies that bind to p53-mhc class i complex | |
GB201718734D0 (en) | Single domain antibodies that bind to CD137 | |
GB201808589D0 (en) | Single domain antibodies that bind CD137 | |
GB201718735D0 (en) | Bispecific molecules that bind to CD137 and PSMA |